Literature DB >> 8453928

Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography.

H J Brambs1, C D Claussen.   

Abstract

Ultrasound remains the most readily available and least expensive of the imaging techniques used in assessment of the upper abdomen. Ultrasound is very useful in the detection of pancreatic tumors as well as in the evaluation of the extent of the disease. If ultrasound fails technically or is inconclusive, CT is recommended. Determination of CA 19-9 may help to decide whether ultrasound should be followed by CT or other examinations (51). Patients with any equivocal or inconclusive abnormality on ultrasound or CT should undergo ERCP. Even when ultrasound and CT of the pancreas appear normal there may be an indication for performing ERCP if the clinical suspicion of pancreatic cancer is still strong (52). Angiography is a reliable method of assessing major vascular tumor involvement, which to most surgeons would be a sign of unresectability. Although for some investigators CT is superior to angiography in assessing vascular involvement, angiography is performed preoperatively in many cases because it delineates the vascular anatomy, which can be abnormal in up to one third of patients. Percutaneous biopsy is an important technique for confirming the radiologic diagnosis of unresectable pancreatic carcinoma, particularly for differentiating pancreas carcinoma from other focal pancreatic lesions such as islet cell tumor, lymphoma, and chronic pancreatitis.

Entities:  

Mesh:

Year:  1993        PMID: 8453928     DOI: 10.1055/s-2007-1009126

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  8 in total

1.  Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.

Authors:  Michael Haas; Rüdiger P Laubender; Petra Stieber; Stefan Holdenrieder; Christiane J Bruns; Ralf Wilkowski; Ulrich Mansmann; Volker Heinemann; Stefan Boeck
Journal:  Tumour Biol       Date:  2010-05-18

2.  CA19-9-related tumor kinetics after first-line chemotherapy of patients with advanced pancreatic cancer: a monoinstitutional experience.

Authors:  Giuseppe Colloca; Antonella Venturino; Domenico Guarneri
Journal:  Med Oncol       Date:  2016-08-13       Impact factor: 3.064

3.  "Mass-forming" pancreatitis masquerades as pancreatic carcinoma.

Authors:  K Yamaguchi; K Chijiiwa; S Saiki; A Nakatsuka; M Tanaka
Journal:  Int J Pancreatol       Date:  1996-08

Review 4.  Pancreatic cancer: can we screen? How should we stage?

Authors:  A A Parikh; A M Lowy
Journal:  Curr Gastroenterol Rep       Date:  1999-04

5.  CT arterial portography in the staging of pancreatic malignancy.

Authors:  S Varshney; C N Hacking; C D Johnson
Journal:  Int J Pancreatol       Date:  2000-08

6.  Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.

Authors:  Todd M Bauer; Bassel F El-Rayes; Xiaobai Li; Nazik Hammad; Philip A Philip; Anthony F Shields; Mark M Zalupski; Tanios Bekaii-Saab
Journal:  Cancer       Date:  2012-07-11       Impact factor: 6.860

Review 7.  Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases.

Authors:  Christin Pilzweger; Stefan Holdenrieder
Journal:  Diagnostics (Basel)       Date:  2015-06-16

Review 8.  Early Diagnosis And Management Of Malignant Distal Biliary Obstruction: A Review On Current Recommendations And Guidelines.

Authors:  Michael Fernandez Y Viesca; Marianna Arvanitakis
Journal:  Clin Exp Gastroenterol       Date:  2019-11-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.